Fayed S T, Ahmad S M, Kassim S K, Khalifa A
Department of Obstetrics and Gynecology, Ain Shams Faculty of Medicine, Cairo, Egypt.
Dis Markers. 1998 Nov;14(3):155-60. doi: 10.1155/1998/738321.
The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of ovarian cancer. Both markers were measured in 30 patients with proven epithelial ovarian cancer, 30 patients with benign pelvic masses and 30 normal women. CA125 and CA72-4 were measured using the luminometric immunoassay and immunoradiometric assay respectively. All patients with ovarian cancer were submitted to surgical staging and cytoreduction followed by adjuvant platinum based chemotherapy for 3-6 courses. Fixing the specificity at 95%, CA125 had a sensitivity of 76.7% at a cut-off 85 u/ml while CA72-4 had a sensitivity of 70% at a cut-off 8.5 u/ml. The combination of CA72-4 with CA125 increased the sensitivity to 95% while fixing the specificity at 95%. Among seven cases with stage I and II ovarian cancer five cases had CA125 level below 85 U/ml, three patients out of them had CA72-4 above 8.5 U/ml. CA 72-4 could reflect the residual disease following cytoreduction and could improve the detection of relapse by CA125.
CA72-4 could complement the standard tumor marker CA125 both in diagnosis and follow up of patients with epithelial ovarian cancer.
肿瘤标志物CA125和CA72 - 4在卵巢癌的诊断和治疗中的作用已得到评估。对30例经证实的上皮性卵巢癌患者、30例盆腔良性肿块患者和30名正常女性进行了这两种标志物的检测。分别采用化学发光免疫分析法和免疫放射分析法检测CA125和CA72 - 4。所有卵巢癌患者均接受了手术分期和肿瘤细胞减灭术，随后进行3 - 6个疗程的铂类辅助化疗。将特异性设定为95%时，CA125在临界值85 U/ml时的灵敏度为76.7%，而CA72 - 4在临界值8.5 U/ml时的灵敏度为70%。CA72 - 4与CA125联合使用时，在将特异性设定为95%的情况下，灵敏度提高到了95%。在7例Ⅰ期和Ⅱ期卵巢癌患者中，5例CA125水平低于85 U/ml，其中3例CA72 - 4高于8.5 U/ml。CA72 - 4能够反映肿瘤细胞减灭术后的残留病灶，并且能够提高CA125对复发的检测能力。
CA72 - 4在上皮性卵巢癌患者的诊断和随访中能够补充标准肿瘤标志物CA125的不足。
